<DOC>
	<DOCNO>NCT02590614</DOCNO>
	<brief_summary>Determine difference serum vitamin D metabolism genetic ancestry .</brief_summary>
	<brief_title>Genetic , Dietary Environmental Influences Vitamin D Metabolism</brief_title>
	<detailed_description>Vitamin D metabolites well-recognized stop cancer cell growth culture . However , clear definition sufficient level serum vitamin D ( currently measure 25 ( OH ) D ) disease prevention hamper inconsistent result observational study randomize clinical trial . Observational cancer study report increase reduced risk cancer subject high serum level 25 ( OH ) D , large randomize trial report significant benefit vitamin D supplementation breast cancer ( incidence ) , colon cancer ( incidence mortality ) , lung cancer ( mortality ) , benign proliferative breast disease . The 25 ( OH ) D metabolite vitamin D ( comprise 25 ( OH ) D3 25 ( OH ) D2 ) , principal hydroxylated metabolite serum consider reasonable functional biomarker vitamin D status . This , although subject seasonal variation , multiple measurement individual relatively consistent time . The biologically active vitamin D metabolite 1,25 ( OH ) 2D3 , may therefore relevant long-term health outcome . Nonetheless , 1,25 ( OH ) 2D3 frequently use biomarker epidemiologic study display diurnal variation short vivo half life . Notably , vivo treatment 1,25 ( OH ) 2D3 associate increase metabolic clearance 25 ( OH ) D3 , decrease serum 25 ( OH ) D3 level , high 25 ( OH ) D3 24,25 ( OH ) 2D3 conversion rate human animal . This suggest use 25 ( OH ) D single biomarker vitamin D status fully capture entire picture . Paradoxically , one individual may classify 'low ' 25 ( OH ) D consequence low dietary intake little sun exposure yet another individual classify 'low ' 25 ( OH ) D may actually high concentration 1,25 ( OH ) 2D3 metabolite—possibly due genetic difference enzymes metabolize vitamin D ( CYP2R1 , CYP27B1 , CYP24A1 ) . Genome-wide candidate gene association study serum 25 ( OH ) D level suggest role single nucleotide polymorphism ( SNPs ) near vitamin D binding protein ( GC ) CYP2R1 . However , investigator others show serum 25 ( OH ) D level also associate genetic ancestry . Because exist study adjust genetic ancestry function SNPs yet establish , know whether SNPs actually play role whether may spurious association due ancestral background ( i.e. , population stratification ) , correlation truly causal SNPs , random chance . In addition , number SNPs must distinguish , genome-wide study capture region high homology sequence repeat , promoter region CYP24A1 high guanine-cytosine content . Improved classification 'low ' 25 ( OH ) D level within context particular genetic background identification `` rapid '' versus `` slow '' vitamin D metabolizers likely important implication cancer risk . It well-recognized individual African Ancestry substantially low ( ~2-fold ) serum 25 ( OH ) D level compare racial/ethnic group . These difference attribute primarily skin pigmentation . However , relation serum 25 ( OH ) D level health outcome complex involves number variable include diet , sun exposure hormone status . For example , despite low average dietary intake calcium vitamin D , low serum 25 ( OH ) D level , African Americans high bone mineral density 3-fold low risk hip fracture relative European Americans . There line evidence suggest African Americans may comparatively higher circulating level 1,25 ( OH ) 2D3 , although study small account age and/or diurnal variation , may explain study report difference . Among Europeans alone , moderately high heritability serum 25 ( OH ) D level ( ~50 70 % 25 ( OH ) D ) observe , well association 25 ( OH ) D several genetic polymorphism vitamin D metabolize enzymes , although functional consequence polymorphisms know . Small large clinical trial among healthy individual also note substantial inter-individual difference ( much 5-fold ) increase serum 25 ( OH ) D level among participant give oral dose vitamin D , minimal erythema dose ( MED ) UV-B light , dose UV light . The importance understand inter-individual difference vitamin D synthesis , metabolism effect underscored result high dose randomize trial report vitamin D supplementation group experience 31 % high bone fracture incidence , significantly low prostate cancer survival . There clear need understand individual difference metabolism vitamin D future high dose trial proceed . Previous Data : Studies investigator ' lab others identify significant racial/ethnic difference frequency variant gene responsible vitamin D metabolism ( i.e. , CYP2R1 , CYP27B1 CYP24A1 ) . In collaboration Pike Laboratory ( University Wisconsin ) , investigator ' laboratory identify several novel genetic variant recently identify regulatory region gene encodes major vitamin D catabolic enzyme ( CYP24A1 ) . Study Rationale : The role/function polymorphism test either epidemiologic association study cell-based assay . It important complement genetic association study multiple type molecular assay tell consistent story likely role particular genetic variant . The investigator hypothesize significant influence genetic variant serum vitamin D metabolism independent genetic ancestry , skin melanin content , sunlight exposure dietary/supplement intake . Study Objectives : A small randomize study healthy subject investigate temporal change balance metabolite ( 25 ( OH ) D3 , 25 ( OH ) D2 , 24,25 ( OH ) 2D3 1,25 ( OH ) 2D3 ) follow two-month course vitamin D3 ( 800 IU/d ) . This study overcome limitation exist genetic association study may report spurious result due lack control genetic ancestry , skin reflectance , collection blood specimen summer month , use assay distinguish 25 ( OH ) D2 25 ( OH ) D3 . The advantage study : 1 ) match design incorporate temporal assessment vitamin D metabolism , 2 ) genetic Ancestry Informative Markers ( AIMs ) , 3 ) melanin skin index , 4 ) sensitive reliable assay four serum vitamin D metabolites , 5 ) functional molecular assay relate specific genetic polymorphism . The investigator ' research address one major research gap understand health-related benefit vitamin D identify recent Institute Medicine Review . While vitamin D metabolites significant anti-cancer property , good understanding genetic influence upon vitamin D metabolism need order improve identification cancer risk associate vitamin D. Study Design : This study employ two designs—first cross-sectional study participant select . Among cross-sectional study participant , subset randomly select match base genetic ancestry , randomize either intervention ( 800 IU/day vitamin ) placebo group . Statistical Plan : In first portion study , estimate 400 participant screen determine eligibility . Eligibility screen complete online RedCap . In second portion study , participant randomly choose original 400 Supplement Intervention Study ask complete 3 additional blood draw Week 0 , 4 8 Supplement Intervention Study ( N=64 ) . The 64 Supplement Intervention study participant randomly choose eligible participant first part study ( n=400 ) . Sample size calculation perform Dr. Vernon Chinchilli order estimate number participant investigator would need order detect difference vitamin D level . The investigator account loss-to-follow-up normal withdrawal study . NOTE : The total participant get screen change ( original AICR grant ) revise budget 300 400 participant . The investigator make revision investigator decide loss follow-up may higher originally estimate 10 % . The investigator estimate loss follow-up may actually closer 20 % . This proportional difference calculate investigator ' original estimate 52 64 ( 24 % increase participant ) revise also increase amount participant investigator screen original 300 estimate 372 ( determine proportionally 24 % increase ) . The investigator go ahead assume upper limit may include 400 participant investigator end 64 participant supplementation trial . The investigator conduct intention-to-treat analysis analyze difference serum level vitamin D metabolites vitamin D metabolite ratio within supplement placebo group pair times 0 , 1 month 2 month . Differences pairwise log concentration metabolite log metabolite ratio test Wilcoxon Signed-Rank Tests linear mixed-effect model ( SAS Proc Mixed ) use restrict maximum likelihood estimation account one time point well repeat measure vitamin D metabolite . Potential confound effect modification dietary intake vitamin D assess .</detailed_description>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Healthy African American Caucasian adult volunteer 2 . Aged 18 35 3 . At least 50 % African American least 50 % Caucasian 4 . Willing take vitamin D supplement two month 5 . Willing attend monthly visit clinic blood draw vital check 6 . Willing refrain take dietary supplement include herbal supplement , multivitamin vitamin D supplement supplement provide trial . 7 . Willing avoid tanning bed use mention period . 8 . Willing avoid extensive use analgesic consumption follow drug record : Acetaminophen , Celecoxib , Codeine , Fentanyl , antibiotic , Hormonal IUD . 1 . Participants fever ( 100 degree F high ) time visit 2 . Participants severe chronic disease ( i.e. , chronic kidney disease , cirrhosis liver , heart attack , HIV/AIDS , alcoholism , hemophilia , sickle cell disease , serious underlie illness prevents blood donation ) , 3 . Participants receive radiation therapy chemotherapy within past 4 week , 4 . Participants follow upper right arm : rash , cast , swell , paralysis , open sore wound . 5 . Individuals blindness and/or deafness 6 . Pregnant participant exclude study . 7 . Participants take follow medication exclude study : 1 . Longterm antibiotic use : Clarithromycin , Ciprofloxacin , Erythromycin , Telithromycin , Nafcillin 2 . Chemotherapy cancer 3 . Prescription vitamin supplement 4 . Anticonvulsants : Carbamazepine , Pentobarbital , Phenobarbital , Phenytoin , Primidone , Fosphenytoin 5 . Erectile dysfunction drug : sildenafil , vardenafil , tadalafil 6 . Immunosuppressants : Tacrolimus , Cyclosporine A , Sirolimus , Mycophenolate , Glucocorticoids ( like Dexamethasone ) 7 . Protonpump inhibitor : omeprazole lansoprazole , dexlansoprazole , rabeprazole , pantoprazole , esomeprazole 8 . Calcium Channel Blockers : nifedipine , felodipine , isradipine , nicardipine , nifedipine , nisoldipine , amlodipine , lacidipine , Verapamil , diltiazem 9 . Diuretics : furosemide , bumetanide , torsemide , ethacrynic acid , amiloride , triamterene , spironolactone , eplerenone , 10 . Statins : lovastatin , simvastatin , atorvastatin , Pravastatin , fluvastatin , rosuvastatin , pitavastatin , Orlistat ( Xenical , Alli ) , 11 . Antifungal : Itraconazole , Ketoconazole , Posaconazole , Voriconazole , Fluconazole , Isavuconazole ( isavuconazonium sulfate ) Clotrimazole 12 . HIV protease inhibitor antiretrovirals : Atazanavir , Boceprevir , Darunavir , Indinavir , Lopinavir , Nelfinavir , Ombitasvirparitaprevirritonavir , Ombitasvirparitaprevirritonavir plus dasabuvir , Ritonavir ritonavir contain coformulations , Saquinavir , Telaprevir 13 . TB medication : Rifabutin , Rifampin ( rifampicin ) , Rifapentine 14 . As well CYP3A4 inhibitor include : Ceritinib , Cobicistat cobicistat contain coformulations , Idelalisib , Nefazodone , Amiodarone , Aprepitant , Cimetidine , Conivaptan , Crizotinib , Delavirdine , Desipramine , Dronedarone , Fosaprepitant Mifepristone , Netupitant , Nilotinib , Tibolone 15 . As well CYP3A4 inducer include : Dexamethasone , Enzalutamide , Lumacaftor , Mitotane , St. John 's wort , Bexarotene , Bosentan , Dabrafenib , Efavirenz , Eslicarbazepine , Etravirine , Modafinil 16 . Other drug cause participant exclude include : Cholestyramine , Ferric carboxymaltose ( treatment iron deficiency anemia ) , Dapsone , Metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>